Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: April 27, 2017

DrugPatentWatch Database Preview

MEXILETINE HYDROCHLORIDE Drug Profile

« Back to Dashboard

What is the patent landscape for Mexiletine Hydrochloride, and when can generics launch?

Mexiletine Hydrochloride is a drug marketed by Watson Labs, Idt Australia Ltd, and Teva. and is included in four NDAs.

The generic ingredient in MEXILETINE HYDROCHLORIDE is mexiletine hydrochloride. There are five drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the mexiletine hydrochloride profile page.

Summary for Tradename: MEXILETINE HYDROCHLORIDE

Patents:0
Applicants:3
NDAs:4
Suppliers / Packagers: see list5
Bulk Api Vendors: see list66
Clinical Trials: see list998
Patent Applications: see list803
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:MEXILETINE HYDROCHLORIDE at DailyMed

Pharmacology for Tradename: MEXILETINE HYDROCHLORIDE

Drug ClassAntiarrhythmic
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Watson Labs
MEXILETINE HYDROCHLORIDE
mexiletine hydrochloride
CAPSULE;ORAL074711-001Feb 26, 1997DISCNNoNo► Subscribe► Subscribe
Watson Labs
MEXILETINE HYDROCHLORIDE
mexiletine hydrochloride
CAPSULE;ORAL074865-001Apr 13, 1998DISCNNoNo► Subscribe► Subscribe
Idt Australia Ltd
MEXILETINE HYDROCHLORIDE
mexiletine hydrochloride
CAPSULE;ORAL074450-001May 16, 1996DISCNNoNo► Subscribe► Subscribe
Teva
MEXILETINE HYDROCHLORIDE
mexiletine hydrochloride
CAPSULE;ORAL074377-003May 16, 1995RXNoYes► Subscribe► Subscribe
Watson Labs
MEXILETINE HYDROCHLORIDE
mexiletine hydrochloride
CAPSULE;ORAL074865-002Apr 13, 1998DISCNNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Subscribe for Complete Access

  • Analyze global market entry opportunities
  • Find generic sources and suppliers
  • Set up watchlists for daily email updates

► Plans and Pricing

Expired Orange Book Patents

 Available with subscription

Paragraph IV Activity

 Available with subscription

Patent Maintenance

 Available with subscription

Non-Orange Book Patents

 Available with subscription

International Patents

 Available with subscription

Supplementary Protection Certificates

 Available with subscription

« Back to the Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot